CFTR functional measurements in human models for diagnosis, prognosis and personalized therapy. Report on the pre-conference meeting to the 11th ECFS Basic Science Conference, Malta, 26-29 March 2014.

Journal of Cystic Fibrosis

Volumn 13, Issue 4, 2014, Pages 363-372

  Beekman, Jeffrey M ^a   Sermet Gaudelus, Isabelle ^b   De Boeck, Kris ^c   Gonska, Tanja ^d   Derichs, Nico ^e   Mall, Marcus A ^f   Mehta, Anil ^g   Martin, Ulrich ^h   Drumm, Mitch ⁱ   Amaral, Margarida D ^j  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b INSERM   (France)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g UNIVERSITY OF DUNDEE   (United Kingdom)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF LISBON   (Portugal)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHYLLINE; ATROPINE; BIOLOGICAL MARKER; CHLORIDE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ISOPRENALINE; IVACAFTOR; LUMACAFTOR; CFTR PROTEIN, HUMAN; DNA;

ADULT STEM CELL; BIOASSAY; CELL CULTURE; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; CYSTIC FIBROSIS; CYTOPLASM; DIAGNOSTIC TEST; DISEASE SEVERITY; EPITHELIUM; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IN VIVO STUDY; INTESTINAL CURRENT MEASUREMENT; INTESTINE EPITHELIUM; LUNG PARENCHYMA; MUTATION; NONHUMAN; NOSE MUCOSA; PANCREAS FUNCTION; PERSONALIZED MEDICINE; PLURIPOTENT STEM CELL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; QUANTITATIVE ANALYSIS; RECTAL EPITHELIUM; RECTUM BIOPSY; RESPIRATORY EPITHELIUM; SENSITIVITY AND SPECIFICITY; SWEAT GLAND; SWEATING; GENE THERAPY; GENETIC PROCEDURES; GENETICS; GENOTYPE; MALTA; METABOLISM; ORGANIZATION; PROCEDURES;

CONGRESSES AS TOPIC; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DNA; GENETIC TECHNIQUES; GENETIC THERAPY; GENOTYPE; HUMANS; MALTA; MUTATION; PROGNOSIS;

EID: 84902343264     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2014.05.007     Document Type: Conference Paper

References (69)

1. Riordan J.R. CFTR function and prospects for therapy. Annu Rev Biochem 2008, 77:701-726.
2. Sosnay P.R., Siklosi K.R., Van Goor F., Kaniecki K., Yu H., Sharma N., et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet 2013, 45:1160-1167.
3. Zielenski J. Genotype and phenotype in cystic fibrosis. Respiration 2000, 67:117-133.
4. De Boeck K., Kent L., Davies J., Derichs N., Amaral M., Rowe S., et al. CFTR biomarkers: time for promotion to surrogate endpoint?. Eur Respir J 2012, 14:38. 10.1186/1465-9921-14-38.
5. Accurso F.J., Rowe S.M., Clancy J.P., Boyle M.P., Dunitz J.M., Durie P.R., et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010, 363:1991-2003.
6. Ramsey B.W., Davies J., McElvaney N.G., Tullis E., Bell S.C., Dřevínek P., et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011, 365:1663-1672.
7. VX809 combo therapy. Lancet Resp Med n.d., 2014 [in press].
8. - secretion in human rectal biopsies constitute a robust biomarker for cystic fibrosis diagnosis and prognosis. PLoS One 2012, 7:e47708.
9. - channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis. Gastroenterology 2004, 127:1085-1095.
10. Derichs N., Sanz J., Kanel Von T., Stolpe C., Zapf A., Tümmler B., et al. Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data. Thorax 2010, 65:594-599.
11. Gibson L.E., Cooke R.E. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics 1959, 23:545-549.
12. Farrell P.M., Rosenstein B.J., White T.B., Accurso F.J., Castellani C., Cutting G.R., et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 2008, 153:S4-S14.
13. Gonska T., Choi P., Stephenson A., Ellis L., Martin S., Solomon M., et al. Role of cystic fibrosis transmembrane conductance regulator in patients with chronic sinopulmonary disease. Chest 2012, 142:996-1004.
14. Wilschanski M., Dupuis A., Ellis L., Jarvi K., Zielenski J., Tullis E., et al. Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. Am J Respir Crit Care Med 2006, 174:787-794.
15. Highsmith W.E., Burch L.H., Zhou Z., Olsen J.C., Boat T.E., Spock A., et al. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med 1994, 331:974-980.
16. Burgel P.-R., Fajac I., Hubert D., Grenet D., Stremler N., Roussey M., et al. Non-classic cystic fibrosis associated with D1152H CFTR mutation. Clin Genet 2010, 77:355-364.
17. Gonska T., Ip W., Turner D., Han W.S., Rose J., Durie P., et al. Sweat gland bioelectrics differ in cystic fibrosis: a new concept for potential diagnosis and assessment of CFTR function in cystic fibrosis. Thorax 2009, 64:932-938.
18. Quinton P., Molyneux L., Ip W., Dupuis A., Avolio J., Tullis E., et al. β-Adrenergic sweat secretion as a diagnostic test for cystic fibrosis. Am J Respir Crit Care Med 2012, 186:732-739.
19. Reddy M.M., Quinton P.M. Altered electrical potential profile of human reabsorptive sweat duct cells in cystic fibrosis. Am J Physiol 1989, 257:C722-C726.
20. Quinton P.M. Chloride impermeability in cystic fibrosis. Nature 1983, 301:421-422.
21. Behm J.K., Hagiwara G., Lewiston N.J., Quinton P.M., Wine J.J. Hyposecretion of beta-adrenergically induced sweating in cystic fibrosis heterozygotes. Pediatr Res 1987, 22:271-276.
22. Sato K., Sato F. Variable reduction in beta-adrenergic sweat secretion in cystic fibrosis heterozygotes. J Lab Clin Med 1988, 111:511-518.
23. Veeze H.J., Sinaasappel M., Bijman J., Bouquet J., de Jonge H.R. Ion transport abnormalities in rectal suction biopsies from children with cystic fibrosis. Gastroenterology 1991, 101:398-403.
24. Veeze H.J., Halley D.J., Bijman J., de Jongste J.C., de Jonge H.R., Sinaasappel M. Determinants of mild clinical symptoms in cystic fibrosis patients. Residual chloride secretion measured in rectal biopsies in relation to the genotype. J Clin Invest 1994, 93:461-466.
25. Bronsveld I., Mekus F., Bijman J., Ballmann M., Greipel J., Hundrieser J., et al. Residual chloride secretion in intestinal tissue of deltaF508 homozygous twins and siblings with cystic fibrosis. The European CF Twin and Sibling Study Consortium. Gastroenterology 2000, 119:32-40.
26. De Jonge H.R., Ballmann M., Veeze H., Bronsveld I., Stanke F., Tümmler B., et al. Ex vivo CF diagnosis by intestinal current measurements (ICM) in small aperture, circulating Ussing chambers. J Cyst Fibros 2004, 3(Suppl. 2):159-163.
27. Hug M.J., Derichs N., Bronsveld I., Clancy J.P. Measurement of ion transport function in rectal biopsies. Methods Mol Biol 2011, 741:87-107.
28. Mall M., Bleich M., Schürlein M., Kühr J., Seydewitz H.H., Brandis M., et al. Cholinergic ion secretion in human colon requires coactivation by cAMP. Am J Physiol 1998, 275:G1274-G1281.
29. Mall M., Wissner A., Seydewitz H.H., Kuehr J., Brandis M., Greger R., et al. Defective cholinergic Cl(-) secretion and detection of K(+) secretion in rectal biopsies from cystic fibrosis patients. Am J Physiol Gastrointest Liver Physiol 2000, 278:G617-G624.
30. Kunzelmann K., Mall M. Electrolyte transport in the mammalian colon: mechanisms and implications for disease. Physiol Rev 2002, 82:245-289.
31. Mall M., Hirtz S., Gonska T., Kunzelmann K. Assessment of CFTR function in rectal biopsies for the diagnosis of cystic fibrosis. J Cyst Fibros 2004, 3(Suppl. 2):165-169.
32. Mall M., Kreda S.M., Mengos A., Jensen T.J., Hirtz S., Seydewitz H.H., et al. The DeltaF508 mutation results in loss of CFTR function and mature protein in native human colon. Gastroenterology 2004, 126:32-41.
33. Mall M., Wissner A., Seydewitz H.H., Hübner M., Kuehr J., Brandis M., et al. Effect of genistein on native epithelial tissue from normal individuals and CF patients and on ion channels expressed in Xenopus oocytes. Br J Pharmacol 2000, 130:1884-1892.
34. + channel opener 1-EBIO potentiates residual function of mutant CFTR in rectal biopsies from cystic fibrosis patients. PLoS One 2011, 6:e24445.
35. Clancy J.P., Szczesniak R.D., Ashlock M.A., Ernst S.E., Fan L., Hornick D.B., et al. Multicenter intestinal current measurements in rectal biopsies from CF and non-CF subjects to monitor CFTR function. PLoS One 2013, 8:e73905.
36. De Boeck K., Derichs N., Fajac I., de Jonge H.R., Bronsveld I., Sermet I., et al. New clinical diagnostic procedures for cystic fibrosis in Europe. J Cyst Fibros 2011, 10(Suppl. 2):S53-S66.
37. Derichs N., Pinders-Kessler L., Bronsveld I., Scheinert S., Rückes-Nilges C., de Jonge H.R., et al. Multicenter European standardization and reference values for intestinal current measurement in rectal biopsies. Pediatr Pulmonol Suppl 2013, S36:300.
38. Scheinert S., Pinders L., Klosinski M., Derichs N. Reliability of intestinal current measurement as CFTR biomarker and responsiveness to oral ivacaftor treatment. J Cyst Fibros 2013, 12(S1):S62.
39. Scheinert S., Pinders L., Derichs N. Ex vivo effect of CFTR modulators VX770, VX809 and PTC124 on CFTR-mediated chloride secretion in rectal biopsies from CF patients. J Cyst Fibros 2013, 12(S1):S14.
40. Servidoni M.F., Sousa M., Vinagre A.M., Cardoso S.R., Ribeiro M.A., Meirelles L.R., et al. Rectal forceps biopsy procedure in cystic fibrosis: technical aspects and patients perspective for clinical trials feasibility. BMC Gastroenterol 2013, 13:91.
41. Cohen-Cymberknoh M., Yaakov Y., Shoseyov D., Shteyer E., Schachar E., Rivlin J., et al. Evaluation of the intestinal current measurement method as a diagnostic test for cystic fibrosis. Pediatr Pulmonol 2013, 48:229-235.
42. Sato T., Clevers H. Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications. Science 2013, 340:1190-1194.
43. Dekkers J.F., Wiegerinck C.L., De Jonge H.R., Bronsveld I., Janssens H.M., de Winter-de Groot K.M., et al. A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nat Med 2013, 19:939-945.
44. Dekkers J.F., der Ent van C.K., Beekman J.M. Novel opportunities for CFTR-targeting drug development using organoids. Rare Dis 2013, 1:e27112.
45. Okiyoneda T., Veit G., Dekkers J.F., Bagdany M., Soya N., Xu H., et al. Mechanism-based corrector combination restores DF508-CFTR folding and function. Nat Chem Biol 2013, 9:444-454.
46. Eckford P.D.W., Ramjeesingh M., Molinski S., Pasyk S., Dekkers J.F., Li C., et al. VX-809 and related corrector compounds exhibit secondary activity stabilizing active F508del-CFTR after its partial rescue to the cell surface. Chem Biol 2014, [Apr 8. Epub ahead of print]. 10.1016/j.chembiol.2014.02.021.
47. Schwank G., Koo B.-K., Sasselli V., Dekkers J.F., Heo I., Demircan T., et al. Brief report. Stem Cell 2013, 13:653-658.
48. Hollenhorst M.I., Richter K., Fronius M. Ion transport by pulmonary epithelia. J Biomed Biotechnol 2011, 2011:1-16.
49. Dimova S., Brewster M.E., Noppe M., Jorissen M., Augustijns P. The use of human nasal in vitro cell systems during drug discovery and development. Toxicol In Vitro 2005, 19:107-122.
50. Fulcher M.L., Randell S.H. Human nasal and tracheo-bronchial respiratory epithelial cell culture. Methods Mol Biol 2013, 945:109-121.
51. Karp P.H., Moninger T.O., Weber S.P., Nesselhauf T.S., Launspach J.L., Zabner J., et al. An in vitro model of differentiated human airway epithelia. Methods for establishing primary cultures. Methods Mol Biol 2002, 188:115-137.
52. Pier G.B., Zulianello L. Airway epithelial (nasal) cell monolayers used to study pseudomonas aeruginosa invasion are hyperpolarized and not representative of the human airway epithelium. Infect Immun 2006, 74:7043-7044.
53. Masvidal L., Igreja S., Ramos M.D., Alvarez A., de Gracia J., Ramalho A., et al. Assessing the residual CFTR gene expression in human nasal epithelium cells bearing CFTR splicing mutations causing cystic fibrosis. Eur J Hum Genet 2013, 22:784-791.
54. Clarke L.A., Sousa L., Barreto C., Amaral M.D. Changes in transcriptome of native nasal epithelium expressing F508del-CFTR and intersecting data from comparable studies. Respir Res 2013, 14:38.
55. Ramalho A.S., Clarke L.A., Amaral M.D. Quantification of CFTR transcripts. Methods Mol Biol 2011, 741:115-135.
56. Roxo Rosa M., da Costa G., Luider T.M., Scholte B.J., Coelho A.V., Amaral M.D., et al. Proteomic analysis of nasal cells from cystic fibrosis patients and non-cystic fibrosis control individuals: search for novel biomarkers of cystic fibrosis lung disease. Proteomics 2006, 6:2314-2325.
57. Harris C.M., Mendes F., Dragomir A., Doull I.J.M., Carvalho-Oliveira I., Bebok Z., et al. Assessment of CFTR localisation in native airway epithelial cells obtained by nasal brushing. J Cyst Fibros 2004, 3(Suppl. 2):43-48.
58. Carvalho-Oliveira I., Efthymiadou A., Malhó R., Nogueira P., Tzetis M., Kanavakis E., et al. CFTR localization in native airway cells and cell lines expressing wild-type or F508del-CFTR by a panel of different antibodies. J Histochem Cytochem 2004, 52:193-203.
59. Penque D., Mendes F., Beck S., Farinha C., Pacheco P., Nogueira P., et al. Cystic fibrosis F508del patients have apically localized CFTR in a reduced number of airway cells. Lab Invest 2000, 80:857-868.
60. Maurício A.C., Penque D., Amaral M.D., Ferreira K.T. Ionic transport in tall columnar epithelial (TCE) cells obtained by nasal brushing from non-cystic fibrosis (CF) individuals. Acta Med Port 2004, 17:427-434.
61. Suprynowicz F.A., Upadhyay G., Krawczyk E., Kramer S.C., Hebert J.D., Liu X., et al. Conditionally reprogrammed cells represent a stem-like state of adult epithelial cells. Proc Natl Acad Sci U S A 2012, 109:20035-20040.
62. Liu X., Ory V., Chapman S., Yuan H., Albanese C., Kallakury B., et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am J Pathol 2012, 180:599-607.
63. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
64. Haase A., Olmer R., Schwanke K., Wunderlich S., Merkert S., Hess C., et al. Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell 2009, 5:434-441.
65. Olmer R., Lange A., Selzer S., Kasper C., Haverich A., Martin U., et al. Suspension culture of human pluripotent stem cells in controlled, stirred bioreactors. Tissue Eng Part C Methods 2012, 18:772-784.
66. Huang S.X.L., Islam M.N., O'Neill J., Hu Z., Yang Y.-G., Chen Y.-W., et al. Efficient generation of lung and airway epithelial cells from human pluripotent stem cells. Nat Biotechnol 2014, 32:84-91.
67. Merkert S., Wunderlich S., Bednarski C., Beier J., Haase A., Dreyer A.-K., et al. Efficient designer nuclease-based homologous recombination enables direct PCR screening for footprintless targeted human pluripotent stem cells. Stem Cell Rep 2014, 2:107-118.
68. Wong A.P., Rossant J. Generation of lung epithelium from pluripotent stem cells. Curr Pathobiol Rep 2013, 1:137-145.
69. Yanagida A., Ito K., Chikada H., Nakauchi H., Kamiya A. An in vitro expansion system for generation of human iPS cell-derived hepatic progenitor-like cells exhibiting a bipotent differentiation potential. PLoS One 2013, 8:e67541.